Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF) announced its participation in the Emerging Growth Conference on July 21, 2021. CEO Dr. Ahmad Doroudian will present the company’s plans at 11:00 AM Eastern Time. Attendees will have the chance to ask questions during the session. Registered investors can also access an archived webcast post-event on EmergingGrowth.com. BetterLife focuses on developing compounds for neurological disorders, including TD-0148A for major depressive disorder and TD-010 for anxiety.

BetterLife Pharma has announced early in vitro results for its COVID-19 antiviral, rhIFN⍺2b (AP-003), showing strong antiviral activity against multiple variants, including Wuhan (EC₅₀=0.51), Alpha, and Beta. Ongoing studies aim to validate these findings against further variants. The company has entered a clinical research agreement to trial AP-003 in COVID-19 patients. CEO Ahmad Doroudian emphasized the significance of these results in combating the pandemic and expressed commitment to broadening AP-003's efficacy against emerging variants.

BetterLife Pharma, a biotechnology company, has made significant advancements in H1 2021, particularly with its second-generation psychedelic compound, TD-0148A, aimed at treating major depressive disorders and other neurological conditions. This non-hallucinogenic LSD derivative is projected for clinical trials in H1 2022. Additionally, BetterLife is advancing its TD-010 compound for benzodiazepine dependency. The company has secured crucial partnerships for research and completed financings totaling CDN$9.16 million to support its initiatives.

BetterLife Pharma has announced funding for research into the anti-depressant effects of TD-0148A, a second-generation LSD derivative, through its collaboration with Carleton University. This funding comes from the Mitacs Accelerate program. The goal is to develop a treatment for severe depression and PTSD, addressing the unmet needs in psychiatric care. Dr. Argel Aguilar-Valles will lead the research using established models to explore TD-0148A's potential without the hallucinogenic side effects. This initiative is a significant step in BetterLife's mission to bring innovative therapies to market.

BetterLife Pharma has engaged Buchanan Communications, a leading UK-based consultancy, to enhance its corporate communications. This collaboration aims to effectively convey the Company's milestones to stakeholders, including potential investors and the media.

Additionally, Buchanan's partnership with The Conscious Fund will bolster investment in the psychedelic medicine sector, which is experiencing growth. BetterLife specializes in developing therapeutic pharmaceuticals, targeting virus infections and cancer treatment through innovative interferon-based technologies.

BetterLife Pharma Inc. will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. CEO Ahmad Doroudian will discuss the Company’s product development and pipeline, with access to the presentation available on-demand starting at 7:00 a.m. EDT. BetterLife focuses on non-hallucinogenic psychedelic therapeutics and is developing interferon-based technologies aimed at treating virus infections and certain cancers. Registration for the conference can be found here.

On June 10, 2021, BetterLife Pharma, a biotech firm focused on developing therapeutic pharmaceuticals, announced partnerships with Proactive Investors and Psychedelic Finance to enhance its visibility in the global investor community. Proactive will cover BetterLife’s news releases and produce video interviews, while Psychedelic Finance will implement a comprehensive marketing campaign. BetterLife is advancing interferon-based drug candidates targeting viral infections, including COVID-19, and cancers. This strategic outreach aims to improve market awareness and investor engagement for the company.

BetterLife Pharma has appointed Mr. Henri Sant-Cassia to its Board of Directors, enhancing its leadership in the psychedelic medicine sector. Sant-Cassia, a veteran in plant medicine and co-founder of The Conscious Fund, brings a decade of experience and a strong network. His past successes include generating over $200 million in company valuations. Alongside his appointment, the company announces the resignation of Mr. Sergei Stetsenko. The new leadership aims to accelerate the development of non-hallucinogenic compounds targeting mental health disorders.

BetterLife Pharma Inc. closed a non-brokered private placement, issuing 1,142,857 common shares at USD$0.70 each for total proceeds of USD$800,000. These funds will support working capital and advance pre-clinical and clinical programs. The shares issued are subject to a four-month hold period. BetterLife is a biotechnology company focused on developing psychedelic treatments for mental disorders and interferon-based technologies to combat viral infections like COVID-19.